Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 3;13(2):362-365.
doi: 10.21037/hbsn-24-37. Epub 2024 Mar 27.

ESMO 2023 pancreatic cancer guidelines signal stepwise progress

Christoph Springfeld  1 , Peter Bailey  2 , Markus W Büchler  3 , John P Neoptolemos  3
Affiliations
Editorial

ESMO 2023 pancreatic cancer guidelines signal stepwise progress

Christoph Springfeld et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Resectable; adjuvant; borderline; neoadjuvant; persister cells.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-24-37/coif). C.S. has served on advisory boards for Astra Zeneca, Bayer, BMS, Roche, Servier, MSD and Taiho. J.P.N. has received grants from the Heidelberger Stiftung Chirurgie, Dietmar Hopp Stiftung GmbH, Bundesministerium für Bildung und Forschung and the Stiftung Deutsche Krebshilfe and consulting fees from BioNTech Advisory Board. The other authors have no conflicts of interest to declare.

Comment on

  • Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O'Reilly EM, Hackert T, Golan T, Prager G, Haustermans K, Vogel A, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Conroy T, et al. Ann Oncol. 2023 Nov;34(11):987-1002. doi: 10.1016/j.annonc.2023.08.009. Epub 2023 Sep 9. Ann Oncol. 2023. PMID: 37678671 No abstract available.

References

    1. Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:987-1002. 10.1016/j.annonc.2023.08.009 - DOI - PubMed
    1. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v56-68. 10.1093/annonc/mdv295 - DOI - PubMed
    1. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 2020;38:1763-73. 10.1200/JCO.19.02274 - DOI - PMC - PubMed
    1. Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:157-68. 10.1016/S2468-1253(22)00348-X - DOI - PubMed
    1. Philip PA, Azar I, Xiu J, et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin Cancer Res 2022;28:2704-14. 10.1158/1078-0432.CCR-21-3581 - DOI - PMC - PubMed